FDA issues guidance on biologics’ exclusivity period

08-08-2014

FDA issues guidance on biologics’ exclusivity period

Hurst Photo / Shutterstock.com

The US Food and Drug Administration (FDA) has issued guidance for biological drug makers about what information they should provide the agency to determine when their products’ marketing exclusivity period should begin, known as the “date of first licensure”.


FDA, biologics, biosimilars, marketing exclusivity, BPCI Act

LSIPR